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Summary
Disruption of adenylyl cyclase type 5 (AC5) knockout (KO) is a
novel model for longevity. Because malignancy is a major cause
of death and reduced lifespan in mice, the goal of this investi-
gation was to examine the role of AC5KO in protecting against
cancer. There have been numerous discoveries in genetically
engineered mice over the past several decades, but few have
been translated to the bedside. One major reason is that it is
difficult to alter a gene in patients, but rather a pharmacological
approach is more appropriate. The current investigation employs
a parallel construction to examine the extent to which inhibiting
AC5, either in a genetic knockout (KO) or by a specific pharma-
cological inhibitor protects against cancer. This study is unique,
not only because a combined genetic and pharmacological
approach is rare, but also there are no prior studies on the extent
to which AC5 affects cancer. We found that AC5KO delayed age-
related tumor incidence significantly, as well as protecting
against mammary tumor development in AC5KO 3 MMTV-HER-
2 neu mice, and B16F10 melanoma tumor growth, which can
explain why AC5KO is a model of longevity. In addition, a Food
and Drug Administration approved antiviral agent, adenine 9-b-D-
arabinofuranoside (Vidarabine or AraAde), which specifically
inhibits AC5, reduces LP07 lung and B16F10 melanoma tumor
growth in syngeneic mice. Thus, inhibition of AC5 is a previously
unreported mechanism for prevention of cancers associated with
aging and that can be targeted by an available pharmacologic
inhibitor, with potential consequent extension of lifespan.
Key words: AC5 inhibitor; adenylyl cyclase (AC) knockoutmice;
angiogenesis; B16F10 melanoma; LP07 lung adenocarcinoma;
MMTV-HER-2 neu mice; tumor protection.
Introduction
A significant impediment to improving cancer therapy is the relatively
small numbers of new tumor-inhibitory mechanisms for which effective
therapies can be developed for translation to patients. One potential
source for discovering novel molecular mechanisms that protect against
malignancy is a longevity model, because a major cause of premature
death in mice can be attributed to this disease process. One such model,
which we discovered and described, is the knockout of adenylyl cyclase
type 5 (AC5). These mice live a third longer than wild-type (WT)
littermates and are protected from the cardiomyopathy of aging (Yan
et al., 2007). Because mice do not generally die of heart disease, but do
die of malignancy, the first goal of this investigation was to determine
whether knockout of AC5 (AC5KO) would protect against spontaneous
tumors over the mouse lifespan and to determine its role in protection
against induced tumors. This investigation identifies for the first time that
knockout of this AC isoform protects against cancer. The results could
not have been predicted, as no prior study has examined the role of AC5
in mediating tumor growth.
Adenylyl cyclase (AC) is a ubiquitous enzyme that catalyzes the
synthesis of cAMP, activating PKA and the cAMP response element-
binding protein (CREB) (Patel et al., 2001; Bos, 2003; Willoughby &
Cooper, 2007). However, the results from previous studies have been
controversial, some supporting and others discounting a role for this
pathway in cancer (Schmidt et al., 1999; Subbaramaiah et al., 2006;
Yano et al., 2007; Sakamoto & Frank, 2009; Chandramouli et al., 2010;
Merkle & Hoffmann, 2011). AC is also a central component of the b-
adrenergic-signaling pathway and interestingly a recent study identifies
b-adrenergic receptor blockers as potential antitumor agents (Ji et al.,
2012; Armaiz-Pena et al., 2013).
Our hypothesis is that the controversy with regard to AC effects on
cancer may potentially be reconciled by identifying which of the nine
major AC isoforms are involved. Each of these regulates function in
different organs, and some of these may actually have opposite effects in
regulation of disease processes. Over the past 25 years, there has been
an explosion of novel transgenic and knockout models engineered in
mice that have an adverse or salutary effect on the malignant disease
process in the mouse, but relatively few have been translated to clinical
application. There are several reasons why so few of these mechanisms
have been translated to the bedside. First, there may be major species
differences. A second, and potentially more important reason, is that it is
difficult to translate disrupting a gene in mouse to human cancer
therapy. To this end, it would be valuable to have a pharmacological
analogue of the disrupted gene. We recently found that a drug, which
was Food and Drug Administration (FDA) approved for antiviral therapy
in patients, Vidarabine, also is a specific inhibitor of AC5 (Plunkett et al.,
1974; Iwatsubo et al., 2012). Accordingly, the next major goal of this
investigation was to determine whether this drug also protects against
malignancy.
Several experimental approaches were employed to prove our
hypothesis: first was to examine retrospectively the incidence of tumors
over the life of AC5KO mice and WT littermates; the second was
prospective, that is, to determine whether mating the AC5KO mice with
MMTV-HER-2 neu mice, which are known to be prone to develop
mammary tumors (Jacquemart et al., 2009), would induce protection in
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the bigenic mice; the third was to examine to which extent AC5KO mice
were protected against syngeneic melanoma tumor growth; the final
goal was to conduct a parallel investigation on the extent to which the
antiviral drug, Vidarabine, which selectively inhibits AC5 (Plunkett et al.,
1974; Iwatsubo et al., 2012), also protects against malignancy. Our
studies demonstrate that inhibition of AC5 may represent a novel
approach to inhibiting spontaneous cancers associated with aging and
mortality.
Results
Our retrospective analysis demonstrated that AC5KO exhibited a
significant delay in age-related tumor incidence (P < 0.01; Fig. 1A),
which can help explain the prolonged longevity in this model (Yan et al.,
2007). The most common type of tumors found were lymphomas,
histiocytic sarcomas, bronchial alveolar carcinomas, schwannomas, and
hepatocarcinomas. Figure 1B shows the percentage of mice that died
with tumors. Clearly, the numbers were dramatically less in AC5KO and
even more so when only mice of the same age at the time of death were
compared (Fig. 1B bar at the right).
The second goal was prospective, that is, to determine whether
mating the AC5KO mice with MMTV-HER-2 neu mice, which are known
to spontaneously develop mammary tumors (Jacquemart et al., 2009),
would induce protection in the bigenic mice. We found that
AC5KO 9 MMTV-Her-2 neu showed a significant delayed age-related
tumor development (P < 0.01) and a lower mammary tumor incidence
(Fig. 1C) compared with AC5WT 9 MMTV-Her-2 neu (P < 0.01). The
results were striking: by day 521 all WT MMTV-Her-2 neu mice
developed mammary carcinomas and died, but there were no deaths
in AC5KO-MMTV-Her-2 neu at that time (Fig. 1C). Representative
histological examples of tumors are shown (Fig. S1, Supporting
information).
It is well known that obesity and diabetes are established risk factors
for the development of postmenopausal breast cancer and are associ-
ated with the increased risk of other cancers, for example, endometrium,
kidney, colon, and esophagus (Calle et al., 2003; Shikata et al., 2013).
Because AC5KO mice have lower body weight and adiposity index than
WT and have better glucose tolerance and insulin resistance (Yan et al.,
2007, 2012; Vatner et al., 2013); these factors may mediate AC5KO
cancer protection. AC5KO mice also have lower leptin levels (AC5KO:
1.99  0.28 vs. WT: 3.23  0.35 ng mL1; P < 0.05) and we con-
firmed that AC5KO 9 MMTV-Her-2 neu mice have significantly lower
body weight (P < 0.01).
The third goal was to examine the extent to which AC5KO mice are
protected against syngeneic tumor growth for which we used the
standard B16F10 melanoma model. After B16F10 melanoma cells of
C57BL/6 origin were inoculated s.c., AC5KO demonstrated decreased
tumor growth compared with AC5WT (P < 0.05 vs. AC5WT). These
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Fig. 1 AC5KO mice have a delayed tumor onset. (A) A retrospective study using female and male mice demonstrated a significantly reduced age-related tumor incidence in
AC5KO mice, **P < 0.01 by log-rank test and by chi-square test; n = 13–15. This figure presents the tumor incidence in the mice undergoing autopsy. The y-axis represents
the accumulated tumor incidence and the x-axis represents the age of mice when tumor was observed. This graph demonstrated that the tumor incidence was delayed in
AC5KO mice. (B) The data from Fig. A were replotted comparing the percentage of animals demonstrating tumors at autopsy for wild-type (WT), all the AC5KO mice and
the smaller subgroup of AC5KO mice that died of similar lifespan as WT (bar at the right). The percentage of AC5KO mice with tumors found at autopsy was significantly less
(P < 0.01) than in WT. (C) Genetically modified AC5KO 9 Neu+/ mice also have delayed age-associated tumor development and reduced mammary tumor incidence,
**P < 0.01 by log-rank test and by chi-square test; n = 13–15, compared with WT 9 Neu+/ mice (See also Fig. S1). (D) AC5KO mice also showed protection against
B16F10 melanoma tumor growth. Tumor growth was significantly reduced in AC5KO mice; **P < 0.01 vs. AC5WT.
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results were striking: at day 27, tumor volume in WT was 6-fold greater
than in AC5KO (Fig. 1D). Tumor latency was doubled in AC5KO vs. WT
(14.1 vs. 6.6 days, P < 0.01), while average wet tumor weight was less
than half in AC5KO (P < 0.01). These data suggest that the effects of
AC5KO might be not only at the level of cellular transformation, but also
at the level of tumor growth and progression.
We next assessed the mechanisms responsible for reduced B16F10
melanoma growth. AC5KO mice were protected through several
mechanisms that regulate tumor growth, for example, angiogenesis,
apoptosis, and tumor cell proliferation (Hanahan & Weinberg, 2000;
Hanahan & Weinberg, 2011). The cell proliferation index was reduced by
over half, and the apoptotic rate was more than doubled in AC5KO
tumors compared with AC5WT (Fig. 2A,B). AC5KO mice are also
protected from tumor angiogenesis and had significantly lower levels of
circulating VEGF in serum compared with AC5WT (Fig. 2C) and tumor
microvascular density (Fig. 2D); P < 0.01. Tumors from AC5KO mice
exhibited less angiogenesis in vivo, as measured by total vessel length
(Fig. 2E, bottom right), P < 0.01.
A fourth goal was to conduct a parallel investigation on the extent to
which the antiviral drug, Vidarabine, which selectively inhibits AC5
(Plunkett et al., 1974; Iwatsubo et al., 2012) also protects against
malignancy. Treatment of B16F10 (Fig. 3B) and LP07 cells (Fig. 4A) with
the AC5 inhibitor reduced forskolin-induced cAMP production
(P < 0.01), demonstrating its ability to block endogenous AC in these
tumor cells. Inhibiting cAMP reduces expression of PKA-CREB-dependent
genes involved in angiogenesis, inflammation, and tumor growth
(Sakamoto & Frank, 2009; Hanahan & Weinberg, 2011) and treatment
with the AC5 inhibitor produced dose-dependent reductions in B16F10,
LP07, and Lewis lung carcinoma cells (LLC1) cell adhesion and migratory
capacity (Fig. 3C,D; Fig. 4B,C; Fig. S2E,F, Supporting information), that
is, additional mechanisms meditating tumor growth and progression.
Our results show that pharmacological AC5 inhibition protects against
tumor growth and against both tumor cell and host mechanisms
facilitating tumor growth (proliferation, adhesion, migration, angiogen-
esis) in syngeneic mouse models and in murine tumor cell lines; for
example, LP07 lung adenocarcinoma (Urtreger et al., 2001; Peluffo
et al., 2004), LLC1, B16F10 melanoma cells (Fig. S2). Using a specific
type 5 AC monoclonal antibody, we showed the expression of AC5 in
B16F10, LP07, and LLC1 cells (Fig. 3A), AC5 inhibitor reduced in vitro
cell proliferation (Fig. S2A,B,C).
In the syngeneic mouse models, the AC5 inhibitor reduced B16F10
(Fig. 3E) and LP07 (Fig. 4D) tumor growth rate and tumor weight
(Fig. 3E inset) compared with vehicle-treated mice (P < 0.05 and
P < 0.05). We measured the intratumor cell proliferation by nuclear
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Fig. 2 Genetic disruption of adenylyl
cyclase type 5 (AC5) protects against
melanoma. Tumors from AC5KO mice
demonstrated significant protection against
melanoma. AC5KO showed decreased cell
proliferation index compared with AC5WT
mice (A), increased apoptosis in melanoma
tumors (by TUNEL assay) (B), and reduced
serum VEGF levels (C). Angiogenesis is
reduced in B16F10 melanoma in AC5KO
mice, as reflected by reduced microvascular
density, with examples shown in
photomicrographs and quantitation in the
bar graph (D), and reduced vessel length
around tumor implants, and with
representative photographs showing
B16F10-induced angiogenesis in each
group of mice (E). **P < 0.01 and
*P < 0.05 vs. AC5WT; n = 4.
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staining of Ki-67 antigen and observed that tumors from AC5 inhibitor-
treated mice exhibited a significantly reduced cell proliferative index
(P < 0.01). In addition, the AC5 inhibitor doubled the apoptotic index in
B16F10 tumors (Fig. 3F) and in LP07 tumors (Fig. 4D, inset). We also
found that the percentage of cells with apoptosis was increased in LP07
cells treated with the AC5 inhibitor (Fig. 4E) along with other indices of
apoptosis, the higher percentage of cells in pre-G0 (Fig. S3A, Supporting
information); the expression of Annexin V (Fig. S3B), and the increased
marker of apoptosis, cleaved caspase-3, along with a concomitant
decrease in the expression of Bcl-2, a known antiapoptotic marker
(Fig. S3C).
The AC5 inhibitor also protected against tumor angiogenesis.
Staining of tumors with CD31 after 22 days of treatment showed that
intratumor microvessel density was reduced by 50% (Fig. 3G, lower
graph). To elucidate the effects of the AC5 inhibitor on endothelial cells,
we used HUVEC cells that have a population doubling time of
approximately 24 h and found that the viability of HUVEC was reduced
with the AC5 inhibitor (50 lM) after 24 h (P < 0.01 vs. vehicle; Fig. S2D).
The AC5 inhibitor also caused a dose-dependent inhibition of endothelial
cell capillary tube formation, which was performed on Matrigel (Fig. 3H,
right side).
One mechanism mediating the reduced angiogenesis with the AC5
inhibitor was VEGF. We also found that AC5 inhibitor treatment reduced
the basal secretion of VEGF (Fig. 4F; P < 0.05) and the forskolin-induced
secretion (P < 0.01). Angiogenesis was also evaluated by staining the
tumors after 30 days of treatment with the AC5 inhibitor or vehicle with
CD31 and found reduced microvascular density. Lastly, in vivo angio-
genesis was also evaluated. The density and length of vessels induced by
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Fig. 3 Pharmacological inhibition of
adenylyl cyclase type 5 (AC5) reduces
B16F10 mouse melanoma growth. (A) AC5
protein is expressed in LP07 and LLC1 lung
carcinoma and B16F10 melanoma cells.
(B) B16F10 tumor cells were pretreated for
10 min in basal medium with the AC5
inhibitor (0–5 lM) and then treated with
forskolin or vehicle for 15 min. Forskolin
(FrsK, 10 lM) increase in cAMP was
reduced by AC5 inhibitor in a dose-
dependent manner in B16F10 cells. The
AC5 inhibitor reduced in vitro tumor cell
adhesion (C) and migration (D).
(E) Treatment with the AC5 inhibitor,
50 mg kg1 day1, reduced melanoma
tumor growth after 8 9 104 B16F10
melanoma cells were inoculated
subcutaneously in the flank of C57B16
mice. Tumor wet weights were significantly
different. *P < 0.05 vs. vehicle; n = 12 per
group (E, small inset). (F) The AC5 inhibitor
increased the intratumor apoptotic index;
*P < 0.05 vs. vehicle; n = 5. (G) The AC5
inhibitor reduced B16F10 melanoma
angiogenesis as reflected by reduced
microvascular density (arrows indicate
microvessels in the tumor) and reduced
endothelial capillary tube formation, with
representative examples shown in (H) (left)
and quantitative data in (H) (right).
*P < 0.05 and **P < 0.01 vs. EGM-2
medium and vehicle; n = 3–12.
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the LP07 tumors were reduced in AC5 inhibitor-treated mice (P < 0.05;
Fig. 4H).
Discussion
There are two major findings in the current investigation. The first is that
disruption of AC5 protects against tumor growth, and the second is that
similar results are observed with a pharmacological inhibitor of AC5. We
identified for the first time that inhibition of a specific isoform of AC,
that is, AC5 protected against cancer. This is significant for several
reasons and may help resolve the prior controversy in the literature, as
prior studies did not examine specific isoforms and as different isoforms
may have different or even opposite effects on any given disease
process. The second major finding is that a pharmacological AC5
inhibitor, Vidarabine, replicates the salutary effects of AC5 disruption.
This is significant, as this allows translation to patients with cancer either
with this compound or one that is engineered for safety and efficacy by
the pharmaceutical industry.
The current investigation was stimulated by our previous study, which
demonstrated increased longevity in AC5KO mice (Yan et al., 2007).
Because a major cause of death in mice is neoplastic disease, we
reasoned syllogistically that AC5KO mice may be protected from this
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reduces lung tumor growth. LP07 cells
were pretreated for 10 min in basal
medium with AC5 inhibitor (0–5 lM),
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production (A); adhesive capacity of LPO7
cells (B); migratory capacity of LPO7 cells
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VEGF (F). (D) Tumor growth induced by
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cause of death, which in turn, protected against premature mortality.
Accordingly, our first goal was to determine the time of death in these
mice and their WT littermates and that were related to tumors. We
found that AC5KO mice have a delayed age-related tumor incidence,
and the most common neoplasms were lymphomas, pulmonary adeno-
mas, histiocytic sarcomas, hepatocarcinomas, schwannomas, and
bronchial alveolar adenomas.
Our next goal was to determine whether the AC5KO mice were
protected from induced tumors. To address this question, we studied
MMTV-Her-2 neu mice, which develop mammary tumors (Jacquemart
et al., 2009). We found that disruption of AC5 leads to a significant
protection against age-related tumors and to a reduction in the
incidence of mammary tumors in AC5KO 9 MMTV-Her-2 neu mice,
compared with controls, which was consistent with our findings of
protection against all naturally developing tumors in aging AC5KO and
WT mice. Our AC5KO 9 MMTV-Her-2 neu mice displayed a reduced
incidence of mammary tumors, but also lymphomas, histiocytic sarco-
mas, and hepatocellular adenomas and carcinomas.
Another feature of AC5KO mice is their protection from obesity,
diabetes, and oxidative stress factors associated with increased cancer
incidence (Yan et al., 2007, 2012; Vatner et al., 2013). This is important
for interpretation of the current results, as it is well known that obesity is
an established risk factor for the development of postmenopausal breast
cancer and is associated with the increased risk for other cancers in
endometrium, kidney, colon, and esophagus. Diabetes has also been
associated with increased incidence of cancer (Shikata et al., 2013).
Importantly, we previously reported that AC5KO mice have lower body
weight and adiposity indices than WT (Yan et al., 2012) and lower levels
of the hormone leptin. Whereas diabetes and obesity are major causes of
morbidity and reduced longevity in humans (Knight, 2011), in mice
cancer is a more important cause of mortality (Storer, 1966; Wolf et al.,
1988; Chrisp et al., 1996). The data from the current investigation
support the concept that AC5 inhibition reduces cancer and by syllogistic
reasoning may be responsible in part for the extended longevity in this
model. The third model employed involved grafting of B16F10
melanoma cells to the mice. AC5KO mice showed reduced tumor
growth compared with WT in this model as well. The reduction in tumor
growth was accompanied by significantly reduced angiogenesis and
increased tumor cell apoptosis in AC5KO mice, two mechanisms that
protect against tumor growth (Hanahan & Weinberg, 2011).
Finally, and potentially most interesting, we found that the antiviral
drug, Vidarabine, previously used in this country and still used in others
for Herpes treatment in patients (De Clercq, 1993), has selective AC5
inhibitory properties (Iwatsubo et al., 2012), and that this drug mimics
the salutary effects of AC5 disruption on protection against cancer. The
drug protected against tumor growth in syngeneic mouse models and in
murine tumor cell lines; for example, LP07 lung adenocarcinoma, LLC1
and B16F10 melanoma cells. It also enhanced mechanisms known to
protect against tumor growth, that is, by reducing proliferation,
adhesion, migration, and angiogenesis, while increasing apoptosis. As
noted above the protection induced by the AC5KO and by the AC5
inhibitor, both involved angiogenic mechanisms, a key regulator of
tumor growth. The data on VEGF and reduced tumor vascular density
support this concept. Although this drug inhibits AC5 strongly, but total
AC activity weakly, suggesting a specific AC5 inhibitor, it is possible that
there is inhibition of other AC isoforms, but unlikely as potent as
inhibition of AC5. One limitation of the studies with the AC5 inhibitor is
that experiments were not extended to old mice. It remains to be
determined if this pharmacological approach mimics the AC5KO model
and extends longevity and reduces cancer incidence in old mice.
In summary, this investigation demonstrates a novel mechanism for
cancer protection, inhibition of AC5, which is unique not only because
this has not been described previously, but also because parallel studies
with a pharmacological inhibitor also supports a protective role for
inhibiting AC5. Because the pharmacological inhibitor is already FDA
approved, the journey from bench to bedside should not be long. The
effects of AC5 inhibition in protecting against obesity, diabetes, and
oxidative stress as well as enhancing exercise capacity, all further support
its potential utility in cancer treatment and/or prevention, as diabetes
and obesity and sedentary lifestyle have all been linked to cancer.
Because cancer is a major cause of death in mice (Storer, 1966; Wolf
et al., 1988; Chrisp et al., 1996) and as we demonstrated less cancer in
the AC5KO mice, then by syllogistic reasoning, these findings may
provide an explanation for the longevity in the AC5KO model. Whereas
this is the first report of a specific AC isoform to exert an effect on
cancer, the prior studies on AC (not isoform specific) have reported
controversial results. This may be because different AC isoforms exert
different effects on cancer. In the future, it will be important to
investigate this hypothesis with different specific AC isoform KO models.
Experimental procedures
Cell culture and reagents
LP07 lung adenocarcinoma cell line was obtained in vitro from a s.c.
passage of the original spontaneous P07 tumor and cultured in MEM
supplemented with 10% FBS, 2 mM L-glutamine and 80 lg mL1
gentamycin (Urtreger et al., 2001; Peluffo et al., 2004). B16F10
melanoma and Lewis lung carcinoma LLC1 cells (ATCC, Manassas, VA,
USA) and human umbilical vein endothelial cells (HUVEC; Lonza
Walkersville Inc., Walkersville, MD, USA) were cultured as described by
the manufactures. Adenine 9-b-D-arabinofuranoside (AraAde, Vidara-
bine or AC5 inhibitor) was purchased from Sigma (St. Louis, MO, USA)
and was dissolved in DMSO as vehicle (0 lM) for in vitro experiments.
Mice
AC5KO mice on C57BL/6 or mixed 129SVJ/C57BL/6 background were
used. FVB/N Tg (MMTVneu) 202Mul/J mice, expressing the WT rat neu
transgene under the control of the mouse mammary tumor promoter
(MMTV-neu), were obtained from Jackson Laboratories (Bar Harbor,
ME). AC5 (WT, HET, KO) mixed 129SVJ/C57BL/6 background, and AC5
(WT, HET, KO) 9 MMTV-neu female mice were obtained and monitored
for tumor incidence along their life. BALB/c and C57BL6, 2–4 month-old
mice were used for the short-term mouse tumor experiments. They were
weight-matched and kept in our Animal Care Division. Mice were housed
in a pathogen-free facility under a 12:12 h light–dark cycle with access to
water and food ad libitum. Studies were approved by the Animal Care and
Use Committees of Clemson University, Instituto de Oncologia ‘Angel H.
Roffo’ and New Jersey Medical School.
Tumor experiments
(A) AC5 (WT, HET, KO) experiments: 8 9 104 B16F10 cells (C57BL/6
origin) suspended in 0.2 mL medium were injected s.c into the right
flank of mice (n = 4–9/group). (B) AC5 inhibitor on B16F10 melanoma
growth: miniosmotic pumps (ALZET model 2004, DURECT Corporation)
containing vehicle or AC5 inhibitor (50 mg kg1 day1) were implanted
s.c in C57BL6 mice 3 days after being treated; 8 9 104 B16F10 were
injected into the right flank of mice (n = 14/group) and treatments
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continued till the end of the experiment. (C) AC5 inhibitor on LP07 lung
cancer growth: LP07 cells (3 9 105) were inoculated s.c. in the right
flank of mice BALB/c (n = 9). When tumors became palpable, animals
were treated daily with Vidarabine (50 mg kg1 day1) or vehicle
intraperitoneally during 30 days. Vehicle was a 0.25% sodium car-
boxymethylcellulose solution that was stored at 20 °C, thawed
overnight, and completed with povidone stock solution (4.25%, kept
at 4 °C) to a 0.085% final concentration. Vidarabine (50 mg kg1
day1) or vehicle was prepared weekly, and a magnetic stir bar was
added to the bottle to keep the suspension phase throughout the
dosing. Tumor growth was assessed by measurement of tumor diameter
in the longest dimension (L) and at right angles to that axis (Width, W)
using a Vernier caliper. Tumor volumes were estimated using the
formula, L 9 W 9 W 9 p/6.
Pathology
Half of each tumor was fixed in 10% phosphate-buffered formalin,
dehydrated, and embedded in paraffin. Major organs were subjected to
gross pathology, and tumor slides were stained with haematoxylin-eosin.
Mammary tumors were graded in accordance with criteria of Cardiff
et al. (2000). For the analysis of lymphomas, the evaluation criteria were
described by Kogan et al. (2002).
In vivo angiogenesis
Ten-week-old female AC5WT, AC5HET, AC5KO mice were injected
intradermally in the dorsal midscapular part of mice (n = 5–12/group)
with 8 9 104 B16F10 cells in 250 lL DMEM plus trypan blue (De Lorenzo
et al., 2003) and LP07 (1 9 105) cells in BALB/c mice (n = 5/group) in
0.1 mL MEM plus trypan blue to localize the site of inoculation. After
7 days, mice receiving Vidarabine (50 mg kg1 day1) or vehicle were
euthanized and the inner skin was exposed, and the vascular response
was observed with a dissecting microscope using 6.59 magnification.
Inoculated sites were photographed using a high-resolution camera. A
microscopemicrometer was used to calibrate length inmm. The total length
of vessels was calculated based on the calibration by the Image Pro Plus
software. In vivo angiogenesis was represented by the total length of vessels
around the tumors and expressed as percentage of inhibition comparedwith
AC5WT or vehicle-treated mice.
Proliferation and microvessel density
Tumor cell proliferation and angiogenesis were evaluated by immuno-
staining for Ki-67 (Neo Markers, Fremont, CA, USA) and CD31 (Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) proteins, respectively.
Proliferation was assessed by counting the number of tumor cells with
positive nuclei (for Ki-67) at 4009 magnification. Ten fields were
counted per sample and results were expressed as the proliferation
index: proportion of the positively staining cells over the total number of
cells. Microvessel density was assessed by counting the number of CD31
positive vessels at 4009 magnification in the fields with the highest
vascularization (De Lorenzo et al., 2011).
TUNEL assay
Apoptosis was measured by using terminal deoxyribonucleotide
transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) (Roche
Diagnostics, Indianapolis, IN, USA) as described previously (De Lorenzo
et al., 2011).
Immunoassays
VEGF and leptin protein levels were measured by Quantikine immuno-
assay kits (R&D Systems, Minneapolis, MN, USA) following manufac-
turer’s recommendations.
Western blot analysis
The expression of AC5 in tumor cell lines was quantified using a
monoclonal antibody as described previously (Hu et al., 2009). For the
detection of the apoptotic markers, tumor cell monolayers were lysed
and sonicated in RIPA lysis buffer containing 25 mM Tris–HCl (pH 7.6),
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS with
phosphatase inhibitor cocktails 1 and 2 (Sigma), protease inhibitor
cocktail (Thermo Scientific), and 1 mM NaF. Equal amounts of protein
(20–90 lg) were subjected to SDS-PAGE. After electrophoresis, samples
were transferred to millipore immobilon-P membrane and immunoblot-
ted with antibodies against b-actin (as an internal loading control), Bcl-2,
total caspase-3 (Santa Cruz Biotechnologies), and cleaved caspase-3
(Cell Signaling).
Cell proliferation assay
LP07, B16F10, LLC1 (ATCC), and HUVEC were seeded in 96-well
(5 9 103), flat-bottomed plates in 10% FBS MEM or DMEM media or
2% FBS EGM-2 and allowed to adhere overnight. Then, fresh medium
containing vehicle or Vidarabine (0–50 lM) in serum-free or 2% FBS
medium was added. At 24–72 h, the culture medium was replaced with
3-[4, 5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide (MTT,
0.5 mg mL1). The reaction was stopped 4 h later by removing the
medium and then adding 100 lL DMSO. Absorbance was measured
after 30 min at 560 nm in a 96-well plate reader. IC50 values were
calculated using GraphPad Prism software (GraphPad Software, La Jolla,
CA, USA).
cAMP accumulation assay
cAMP levels in LP07 and B16F10 cells were measured by BiotrakTM
enzyme-immunoassay (GE Healthcare). 2.5 9 103 LP07 lung or 2 9 103
B16F10 melanoma cells were seeded in 96-well plates and incubated
overnight. Different doses of Vidarabine or vehicle were used and
manufacturer’s recommendations were followed to measure cAMP
concentration. Absorbance was measured using a spectrophotometer at
450 nm.
Cell adhesion
105 LP07, LLC1, or B16F10 cells were seeded in 96-well plates in basal
medium containing vehicle or AC5 inhibitor (0–5 lM) and incubated for
90 min. Then, the medium was discarded; cells were fixed, and stained
with 100 lL of methanol/crystal violet solution. After 3 h of incubation,
wells were washed with PBS and then cells were lysed with 250 lL SDS.
Absorbance was measured with spectrophotometer at 595 nm.
Cell migration
(A) LP07 subconfluent monolayers were pretreated overnight with 2%
FBS MEM containing vehicle or Vidarabine (0–5 lM) and 105 LLC1 or
B16F10 cells were seeded on top of the membrane of each transwell
insert in basal DMEM with vehicle or AC5 inhibitor (0–5 lM), and
Anticancer effects of adenylyl cyclase 5 inhibition, M. S. De Lorenzo et al.108
ª 2013 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
migration was evaluated as described previously (Urtreger et al., 2001;
De Lorenzo et al., 2004).
Endothelial capillary tube formation
HUVEC capillary network in vitro was evaluated as previously described
(De Lorenzo et al., 2004). Briefly, MatrigelTM was placed onto 24-well
plates and allowed to gel. HUVEC were grown on 2% FBS- EGM-2
medium. 5 9 104 cells were added per well and cultured in the presence
of vehicle or AC5 inhibitor (0–20 lM) overnight. Using the Imagine Pro
Plus software, the total capillary tube length was calculated.
Cell cycle analysis
LP07 cells were treated with vehicle or Vidarabine (0–5 lM) for 24 and
48 h. Then, cells were trypsinized, washed, suspended in ice-cold PBS
(pH 7.4), counted, and fixed overnight in 50% ethanol at 4 °C. Then,
(106 mL1) cells were resuspended in 1.12% sodium citrate with RNase
A (500 units mL1) for 30 min at 37 °C and then propidium iodide
(50 lg mL1) was added. Red fluorescence of single events was
recorded using an argon ion laser at 488-nm excitation wavelength
and 610-nm emission wavelength to measure DNA index on a Coulter
Epics XL flow cytometer. The percentage of cells present in each phase
of the cell cycle was determined using ModFitLT V2.0 software from
Verity Software House (Topsham, ME, USA). The percentage of
apoptotic cells as well as cells in G0/G1, S, and G2/M phases was
calculated.
Evaluation of apoptotic cells by nuclear staining
LP07 cells were treated with vehicle or Vidarabine (0–5 lM). Thirty-six
hours later, cover slips were stained with DAPI and mounted on slides
with PBS: Glycerol (1:1). Cells were observed for nuclear condensation/
fragmentation as an indicator of apoptosis with a fluorescent micro-
scope. Results were expressed as the percentage of total apoptotic cells
vs. total number of cells.
Annexin-V FITC
Apoptosis was also quantified by flow cytometry by AnnexinV/PI staining
using the Annexin V: fluorescein isothiocyanate Apoptosis Detection Kit I
(BD-Pharmingen, San Diego CA, USA).
Statistical analysis
Statistical comparisons were performed by SPSS (IBM Corporation,
Armonk, NY, USA) and GraphPad InStat (GraphPad Software Inc.,
La Jolla, CA, USA) softwares. Log-rank, Chi-square test, Student’s t-test,
and Fisher exact test were used, and one-way analysis of variance
(ANOVA) was used when comparing more than two groups. After
ANOVA, Tukey–Kramer multiple comparisons test was used. The level of
statistical significance for all tests was P < 0.05.
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Fig. S2 AC5 inhibitor reduces cell proliferation, adhesion and migration.
Fig. S3 AC5 inhibitor increases apoptosis in LP07 cells.
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